Dr David Sheridan Professor Stuart McPherson
| National study of NAFLD management identifies variation in delivery of care in the UK between 2019-2022 | 2023 |
|
Professor David Jones Dr David Sheridan
| A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis | 2022 |
|
Dr David Sheridan Dr Daniel Felmlee Dr Simon Bridge Emeritus Professor Margaret Bassendine
| Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis | 2022 |
|
Dr David Sheridan Professor Quentin Anstee Professor Stuart McPherson
| Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey | 2017 |
|
Emeritus Professor Margaret Bassendine Dr Soren Nielsen Dr Simon Bridge Dr Daniel Felmlee Dr David Sheridan et al. | Hepatitis C virus and atherosclerosis: A legacy after virologic cure? | 2017 |
|
Dr Luca Miele Dr David Sheridan
| Diverse Impacts of the rs58542926 E167K Variant in TM6SF2 on Viral and Metabolic Liver Disease Phenotypes | 2016 |
|
Dr David Sheridan
| FibroGENE: A gene-based model for staging liver fibrosis | 2016 |
|
Dr David Sheridan Fiona Fenwick Emeritus Professor Margaret Bassendine
| Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection | 2016 |
|
Professor Quentin Anstee Dr David Sheridan
| Staging fibrosis and excluding advanced fibrosis in patients with NAFLD: comparison of non-invasive markers in an interim analysis from a prospective multicentre study | 2016 |
|
Dr David Sheridan Professor Margaret Bassendine
| Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease | 2015 |
|
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Emeritus Professor Margaret Bassendine
| Lipidomics analysis of fasting serum identifies novel lipid biomarkers specific for HCV genotype 3 and genotype 1 chronic hepatitis C virus infection | 2015 |
|
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Fiona Fenwick Dr Clare Lanyon et al. | PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism | 2015 |
|
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Dr R Neely Emeritus Professor Margaret Bassendine et al. | Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency | 2014 |
|
Dr David Sheridan Emeritus Professor Margaret Bassendine
| Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection | 2014 |
|
Dr David Sheridan
| IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection | 2014 |
|
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Fiona Fenwick Dr R Neely et al. | Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial | 2014 |
|
Professor Margaret Bassendine Dr David Sheridan Jaime Jonsson
| CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection | 2013 |
|
Dr David Sheridan Dr R Neely Professor Margaret Bassendine
| Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs) | 2013 |
|
Professor Margaret Bassendine Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Dr R Neely et al. | Lipids and HCV | 2013 |
|
Dr David Sheridan Dr Daniel Felmlee Dr Simon Bridge Fiona Fenwick Emeritus Professor Geoffrey Toms et al. | Metabolic Syndrome and Insulin Resistance are Associated with Maximum Hepatitis C Lipoviral Particles in Genotype 1 Infection | 2013 |
|
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Fiona Fenwick Professor Margaret Bassendine et al. | Omega-3 Fatty Acids and/or Fluvastatin in Hepatitis C Prior Non-Responders to Combination Anti-Viral Therapy - A Pilot Randomised Clinical Trial | 2013 |
|
Dr David Sheridan Dr Simon Bridge Dr Daniel Felmlee Emeritus Professor Geoffrey Toms Dr R Neely et al. | Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity | 2012 |
|
Professor Margaret Bassendine Dr David Sheridan
| IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study | 2011 |
|
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Emeritus Professor Geoffrey Toms Professor Margaret Bassendine et al. | Apolipoprotein E and low-density, apolipoprotein B associated lipoviral particles in chronic Hepatitis C infection: Evidence for genotype-specific modulation of lipid pathways | 2011 |
|
Professor Margaret Bassendine Dr David Sheridan Dr Daniel Felmlee Dr Simon Bridge Emeritus Professor Geoffrey Toms et al. | HCV and the hepatic lipid pathway as a potential treatment target | 2011 |
|
Dr Daniel Felmlee Dr David Sheridan Dr Simon Bridge Emeritus Professor Geoffrey Toms Professor Margaret Bassendine et al. | Use of intralipid infusion to analyse apolipoprotein B (APOB) and HCV RNA kinetics in chronic infection | 2011 |
|
Dr David Sheridan Professor Kim Bartlett Dr Daniel Felmlee Dr Simon Bridge Emeritus Professor Geoffrey Toms et al. | Hypocholesterolaemia in chronic hepatitis C genotype 3 infection is due to both reduced cholesterol production and increased LDL clearance | 2010 |
|
Dr David Sheridan Professor Kim Bartlett Dr Daniel Felmlee Dr Simon Bridge Emeritus Professor Geoffrey Toms et al. | Hypocholesterolaemia in chronic Hepatitis C virus (HCV) infection - Reduced production or increased LDL clearance? | 2010 |
|
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Dr Soren Nielsen Dr R Neely et al. | Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection | 2010 |
|
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Dr Soren Nielsen Dr R Neely et al. | Insulin resistance correlates with low density hepatitis C virus particles in genotype 1 infection | 2010 |
|
Dr Daniel Felmlee Dr David Sheridan Dr Simon Bridge Dr Soren Nielsen Emeritus Professor Geoffrey Toms et al. | Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles | 2010 |
|
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Emeritus Professor Geoffrey Toms Dr R Neely et al. | Low density Hepatitis C virus particles (lipoviral particles) associate with insulin resistance in genotype 1 infection | 2010 |
|
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Emeritus Professor Geoffrey Toms Professor Margaret Bassendine et al. | Measurement of low-density Apolipoprotein B associated lipoviral particles in hepatitis C virus genotype 1 infection is more clinically relevant than total viral load | 2010 |
|
Dr Daniel Felmlee Dr David Sheridan Dr Simon Bridge Emeritus Professor Geoffrey Toms Professor Margaret Bassendine et al. | The HCV life-cycle in the vascular compartment | 2010 |
|
Dr Monique Welten Professor Margaret Bassendine Dr David Sheridan Dr James George
| IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy | 2009 |
|
Dr Simon Bridge Dr David Sheridan Dr Daniel Felmlee Dr Soren Nielsen Emeritus Professor Geoffrey Toms et al. | Apolipoprotein B Associated Hepatitis C Virus (HCV): A Minority of Total Viral Load in Patients with Chronic HCV | 2009 |
|
Dr David Sheridan Dr David Price Dr Matthias Schmid Emeritus Professor Geoffrey Toms Dr Peter Donaldson et al. | Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin | 2009 |
|
Dr Daniel Felmlee Dr Simon Bridge Dr David Sheridan Dr Soren Nielsen Emeritus Professor Geoffrey Toms et al. | Large and Buoyant Hepatitis C Virus (HCV) Particles Surge after Patients Consume a High-Fat Meal | 2009 |
|
Dr David Sheridan Dr David Price Dr Matthias Schmid Emeritus Professor Geoffrey Toms
| Apolipoprotein B associated cholesterol level is a predictor of response to therapy in chronic hepatitis C | 2008 |
|